2. “After coronavirus, telemedicine is here to stay”, an article published by the World Bank on 7 July 2020.
Over the next decade, China’s strategic policy initiatives in biomedicine could have broad ramifications for investments in the global pharmaceutical sector and in China itself.
Based on our current growth projections, China is steadily closing the gap between it and the US market. This growth comes as China is already the largest global supplier of active pharmaceutical ingredients, a point that raised concerns during the pandemic given rising geopolitical tensions and policies promoting domestic protectionism.
China’s pharmaceutical market has rapidly grown to become the world’s second largest Billions USD
Data as at September 2020. Sources: IQVIA, GLOBOCAN, World Bank
Elsewhere, telehealth could become a permanent fixture in the way we deliver health care going forward. The idea is that, instead of first stopping in the doctor’s office, the patient’s first stop would be an app.
Such is the case in Mexico, where doctors can monitor the blood sugar levels of their patients remotely using an app developed by Clinicas del Azucar, a health care provider of low-cost diabetes care1. This self monitoring approach allows patients to remain in the comfort of their home, greatly benefitting those living in the remote and rural areas.
View full report here
